Hologic and Biopsy Research Partner For Breast Cancer Detection

Hologic Invests In Biopsy Tech To Improve Breast Cancer Diagnosis

Marlborough, MA - Hologic, Inc. (NASDAQ: HOLX), a leading developer, manufacturer, and supplier of diagnostic products, medical imaging systems, and surgical products dedicated to serving the healthcare industry, today announced a strategic investment in Biopsy Research, Inc. (BRI), a privately held company that has developed a novel breast biopsy technology.

Investment Supports Development Of Minimally Invasive Biopsy Device

The investment will support the development of BRI's minimally invasive biopsy device, which is designed to improve the accuracy and efficiency of breast cancer diagnosis. The device uses a combination of advanced imaging and tissue sampling techniques to provide a more comprehensive view of breast tissue, enabling physicians to better identify and target suspicious lesions.

Hologic's Commitment To Breast Cancer Detection

This investment is part of Hologic's ongoing commitment to improving breast cancer detection and diagnosis. Hologic is a global leader in breast imaging, with a portfolio of products that includes mammograms, breast tomosynthesis, and breast MRI systems. The company's investment in BRI reflects its commitment to providing healthcare providers with the most advanced tools and technologies for detecting and diagnosing breast cancer.

Biopsy Research's Expertise In Breast Biopsy Technology

BRI is a pioneer in the development of breast biopsy technology. The company's team of engineers and scientists has extensive experience in developing and commercializing innovative breast biopsy devices. BRI's technology has the potential to revolutionize the way that breast biopsies are performed, making them more accurate, less invasive, and more effective.

Collaboration To Advance Breast Cancer Detection

Hologic and BRI will work together to develop and commercialize BRI's breast biopsy device. Hologic's global sales and marketing reach will help to bring this technology to healthcare providers around the world. BRI's expertise in breast biopsy technology will ensure that the device is developed to meet the highest standards of quality and performance.

Hologic's CEO Expresses Optimism

"We are excited to partner with Biopsy Research to develop and commercialize this breakthrough breast biopsy technology," said Steve MacMillan, Hologic's Chairman, President, and CEO. "This investment is a testament to our commitment to providing healthcare providers with the most advanced tools and technologies for detecting and diagnosing breast cancer."